bevacizumab

Known as: Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody, Monoclonal Antibody Anti-VEGF 
A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also… (More)

Topic mentions per year

Topic mentions per year

1974-2018
05001000150019742018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
BACKGROUND Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma. PATIENTS AND METHODS Patients… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we… (More)
  • figure 2
Is this relevant?